We used a recombinant lentiviral vector (rLV) for gene delivery of GDNF to the striatum, and assessed its neuroprotective e¡ects in the intrastriatal 6 -hydroxydopamine (6 -OHDA) lesion model.The level of GDNF expression obtained with the rLV-GDNF vector was dose-related and ranged between 0.9^9.3 ng/mg tissue in the transduced striatum, as determined by ELISA, and 0.2^3.0 ng/mg tissue were detected in the ipsilateral substantia nigra (SN), due to anterograde transport of the GDNF protein. GDNF expression was apparent at 4 days and maintained for ! 8 months after injection. Striatal delivery of rLV-GDNF e⁄ciently protected the nigral dopamine (DA) neurons and their projection, against the 6 -OHDA lesion (65^77% of intact side). Sprouting of the lesioned axons was observed along the nigrostriatal pathway, precisely corresponding to the areas containing anterogradely transported GDNF.NeuroReport13:75^82
INTRODUCTION
The VSV-G pseudotyped rLV vector has proved to be a highly efficient vector for gene transfer to postmitotic neurons in the CNS [1] [2] [3] . In the basal ganglia, the rLV vectors may be used to transduce neurons both in the SN and striatum, and stable expression of the transgene, as assessed with reporter genes (b-galactosidase or green fluorescent protein, GFP), has been observed for at least 6 months after vector injection, without any signs of toxicity or adverse inflammatory reaction in the host tissue [1, [4] [5] [6] [7] [8] . The level of expression has been further increased by the introduction of the woodchuck regulatory element (WPRE) into the vector [5, 9] .
The usefulness of the rLV system for delivery of putative therapeutic factors to the brain has recently been explored in rodent and primate models of Parkinson's disease. Expression of GDNF in both SN and striatum has been shown to provide substantial protection of the nigral DA neurons in 6-OHDA lesioned rats [8] as well as in MPTP treated monkeys [7] . Similar protection of the nigral cell bodies has been obtained after injection of the rLV-GDNF vector into the SN alone [4, 5] .
From our own previous studies in 6-OHDA lesioned rats, using either local protein injections [10] or injection of a rAAV-GDNF vector into the SN [11] , it is clear that intranigral GDNF can offer substantial protection of axotomized nigral cell bodies, but that GDNF delivery in the SN alone is unable to preserve the axons projecting to the striatum in 6-OHDA lesioned rats. Moreover, in animals where GDNF is administered at the level of the SN, the GDNF-induced axonal sprouting is confined to the close vicinity of the nigral cell bodies. This may explain why intranigral GDNF induces no or very limited functional recovery in 6-OHDA lesioned animals [10] [11] [12] [13] .
In the present study, we have explored the efficacy of the rLV vector to deliver GDNF to the striatum, and investigated to what extent overexpression of GDNF in the striatum can protect the nigrostriatal DA neurons against 6-OHDA induced toxic damage. We report that intrastriatal rLV-GDNF is highly efficient in rescuing the nigral DA cell bodies and preserving the axons projecting along the nigrostriatal pathway. Although the acute 6-OHDA-induced damage to the DA terminals in the striatum was unaffected in the rLV-GDNF injected animals, substantial regenerative sprouting was induced from the spared axons within the GDNF expressing areas.
MATERIALS AND METHODS
Experimental design: The study was designed to, determine the efficacy of the rLV vector to deliver GDNF to the rat striatum, and to explore whether the level of GDNF expression was sufficient to provide protection of the nigrostriatal DA pathway against a subsequent 6-OHDA injection. In Experiment I, rLV vectors encoding either GFP or GDNF were injected into the striatum, and the timecourse and dose dependence of GDNF expression was determined by ELISA on tissue samples from the striatum and SN. In Experiment II, rLV-GDNF was delivered to the striatum 3 weeks prior to an intrastriatal 6-OHDA lesion, and the animals were killed 3 weeks after the lesion for microscopic analysis of protective effects of GDNF on the nigrostriatal DA system.
Production of the lentiviral vectors:
The rLV-CMV-GFP-W and rLV-CMV-GDNF-W vectors were generated as described previously [8, 14] . Briefly, the transfer constructs and the helper plasmids pCMVDR8.91 and pMD.G were cotransfected into 293T cells. Virions released into the media were collected, the media centrifuged 1.5 h at 26 000 r.p.m., and the pellet dissolved in DNMM. The titer of the rLV-GFP vector stocks were determined to be 6.8 Â 10 8 transducing units (TU)/ml for Experiment I and 1.0 Â 10 7 TU/ml for Experiment II. The titer of infectious particles was determined by serial dilution of the GFP vector on 293T cells. An RNA slot blot technique [15] was subsequently used to determine viral particle titer for both the GFP and GDNF vector. The transducing units of the GDNF expressing vector was estimated based on the ratio between viral particle titer and transducing units as determined for the rLV-GFP vector. The titer of the rLV-GDNF vector stocks were estimated to be 1.8-3.2 Â 10 8 U/ml in Experiment I and 1.0 Â 10 7 TU/ml in Experiment II.
Subjects: A total of 63 adult female Sprague-Dawley rats (B & K Universal, Stockholm, Sweden) were used. The animals were housed under 12:12 h light : dark cycle with free access to food and water. The housing and treatment of the animals was conducted according to the rules set by the Ethical Committee for Use of Laboratory animals at Lund University.
Surgical procedures: For all surgical procedures animals received halothane anesthesia and were placed into a Kopf stereotaxic frame (Kopf Instruments, Tujunga, CA). All injections were made using a 10 ml Hamilton syringe fitted with a glass micropipette. The anterioposterior and mediolateral coordinates were calculated from bregma and the dorsoventral coordinates from the dural surface.
Injection of rLV vectors:
In Experiment I, to determine the dose-response relationship between the number of TU injected and the level of GDNF expression, 16 animals received injections of increasing doses of rLV-GDNF: (1) 3.6 Â 10 4 TU (n = 4); (2) 7.2 Â 10 4 TU (n = 4); ( 3) 1.8 Â 10 5 TU (n = 4) and (4) 3.6 Â 10 5 TU (n = 4). Two 0.5 ml deposits were made at the following coordinates: (1) AP = + 1.2, ML = À2.6, DV = À5.0,À4.0 and (2) AP = +0.5, ML = À3.4, DV = À5.0, À4.0, with the tooth bar set at 0.0. To determine the time course of GDNF expression by rLV delivery, animals received injections of rLV-GDNF (n = 27) or rLV-GFP (n = 9) into the striatum at three sites, 1 ml/site (2 Â 10 5 TU in total of rLV-GDNF and 4 Â 10 5 TU in total of rLV-GFP). The injections were made as two 0.5 ml deposits, along three needle tracts at the following coordinates: (1) AP = +1.4, ML= À2.6, DV = À5.0,À4.0; (2) AP = +0.4, ML= À3.4, DV = À5.0, À4.0; and (3) AP = À0.8, ML = À4.4, DV = À5.0,À4.0. The tooth bar was set at 0.0.
In experiment II, animals received two deposits of 0.5 ml or 2.5 ml rLV-GDNF (n = 10) or rLV-GFP (n = 9) injections into the right striatum at the following coordinates: (1) AP = +1.2, ML = À2.6, DV = À5.0,À4.5 and (2) AP = +0.5, AU = À3.4, DV = À5.0,À4.5, with tooth bar set at 0.0. The rLV-vectors were diluted 1:2, 1:10 or 1:50 in saline and the injected volume was 2 ml for the 1:2 and 1:10 dilutions and 10 ml for the 1:50 dilution. Thus, the animals injected with the 1:2 dilution received 1 Â 10 4 TU in total; the animals injected with rLV at 1:10 or 1:50 dilution received the same total amount of the vector (2 Â 10 3 TU). Since the 1:10 and 1:50 dilutions gave similar results, they were combined in one group, giving a total of four experimental groups: (1) rLV-GFP 2 Â 10 3 TU (n = 6); (2) rLV-GFP 1 Â 10 4 TU (n = 3); (3) rLV-GDNF 2 Â 10 3 TU (n = 6); and (4) rLV-GDNF 1 Â 10 4 TU (n = 4). For quantitative analysis of the number of GFP expressing cells in the striatum, two additional animals (not receiving 6-OHDA) were injected with rLV-GFP bilaterally into the striatum at three sites (coordinates as in Experiment 1) in a total amount of 2 Â 10 6 TU (the undiluted 6.8 Â 10 8 TU/ml vector was used for these animals).
6-OHDA lesions:
A total of 19 animals in Experiment II were re-anesthetized 3 weeks after the rLV injections and received a single deposit of 20 mg 6-OHDA (calculated as free base; Sigma, St. Louis, MO) dissolved in 3 ml ascorbicsaline 0.135% in the right striatum at AP = +1.0, ML = À3.0, DV = À5.0 and tooth bar set at 0.0.
Behavioral analysis: Spontaneous and drug-induced rotation was performed before and after the 6-OHDA lesion to determine whether the rLV injected animals displayed increased activity and asymmetric behavior. The test was performed in automated rotometer bowls. Spontaneous rotation was monitored over 30 min and drug-induced rotation was assessed using D-amphetamine sulfate (Apoteksbolaget; 2.5 mg/kg, i.p.) and rotation was monitored over 90 min. The activity of the animals was assessed by calculating the total number of rotations regardless of the direction. Rotational asymmetry scores are expressed as net 3601 turns/min, with turns towards the injected side assigned a positive value.
GDNF determination by ELISA: At 1 day (n = 4), 4 days (n = 4), 3 weeks (n = 16), 6 weeks (n = 19) and 8 months (n = 9) after rLV injection, the animals were deeply anesthetized with sodium pentobarbital and decapitated. The brains were rapidly removed and placed in a brain slicer. Two coronal slices of 3 mm and 2 mm thickness were cut to cover the striatum, which was dissected dorsal to the anterior commissure and freed from the cortex and septal nuclei. A 2 mm diameter punch centered on the SN was taken from a third 3 mm slice through the midbrain. The frozen tissue samples were sonicated in buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% Triton X-100, 1.7 mg/ml phenylmethylsulfonyl fluoride, 1.0 mg/ml leupeptin, 10 mg/ml aprotinin and 1.0 mg/ml pepstatin) at a tissue concentration of 30 mg/ml. Tissue levels of GDNF were determined on these homo-genates by ELISA according to the supplier's recommendations (G3240, Promega, Madison, WI).
Histology:
The animals in Experiment II were deeply anesthetized with sodium pentobarbital and transcardially perfused with 50 ml isotonic saline followed by 250 ml icecold 4% PFA in 0.1 M phosphate buffer (PB), pH 7.4. The brains were dissected and postfixed in the same fixative for 2 h and transferred into 25% sucrose in 0.1 M PB before sectioning on a freezing microtome at 40 mm. Immunohistochemistry was performed as described previously [8] using antibodies raised against TH enzyme (mouse IgG, 1:2000; Chemicon, Sweden), GFP (chicken IgG, 1:5000; Chemicon, Sweden) and GDNF (rabbit IgG, 1:2000; R & D systems, MN, USA), followed by incubation with biotinylated secondary antibodies (horse anti-mouse, rabbit antichicken, and horse anti-goat, respectively) and avidinbiotin-peroxidase complex (ABC Elite, Vector Laboratories, CA, USA). The color reaction was developed using 3 0 ,3 0 -diaminobenzidine as chromogen. The sections were mounted on chrom-alum coated slides and coverslipped with Depex. Alternate sections were mounted and stained with cresyl violet.
Stereology:
The total numbers of GFP-positive cells in the striatum were estimated by stereology using the optical fractionator [16] . The sections where GFP-positive cells were detected covered an area from the rostral tip of the striatum to the level of the globus pallidus (GP), which yielded 11-12 sections in a series. Sampling was performed using the Olympus CAST-Grid system (Olympus Denmark A/S, Albertslund, Denmark). Using a Â 100 oil objective, a counting frame (3208 mm 2 ) was placed randomly over the first counting area and systematically moved through all counting areas until the entire delineated area was sampled.
Nigral TH-positive cell counts: The number of THpositive neurons in the SN pars compacta was assessed as described previously [17] . In brief, three consecutive sections centered around the level of the medial terminal nucleus of the accessory optic tract (MTN) were used, and all stained cells lateral to the MTN were counted at Â 40 magnification. TH-positive neurons were counted when displaying a nucleus surrounded by TH-immunoreactive (brown) cytoplasm.
Striatal fiber density measurements: Striatal TH-positive innervation was assessed by measuring the optical densities (OD) of the TH-immunoreactive fibers in the striatum using the NIH 1.62 Image program on a Macintosh 9500 computer connected to a digital ProgRes camera and a constant illumination table. OD was measured bilaterally at three rostrocaudal levels over the striatum: (1) AP = +1.0, (2) AP = À0.26, (3) AP = À0.92, relative to bregma [18] , and the readings were corrected for non-specific background by measuring the corpus callosum in each section.
Statistical analysis: Analysis of GDNF expression levels was performed using three-way ANOVA for comparisons between time-points, sides (transduced vs non-transduced) and structures (striatum vs SN). One-way ANOVA was used for comparison between treatments (rLV-GFP vs rLV-GDNF) and Student-Newman-Keuls post-hoc test for differences between groups. Correlation between number of TU of rLV-GDNF injected in the striatum and level of GDNF protein was analyzed using a simple regression analysis.
RESULTS
Expression and distribution of GFP: Expression of the GFP transgene was studied 3-6 weeks following injection of the rLV vector into the striatum in doses varying from 2 Â 10 3 to 2 Â 10 6 TU. In the higher dose group, GFP expressing cells were found distributed in a 0.7-1.2 mm wide and 2.2-3.0 mm deep column along the needle tract (Fig. 1a) . The transduction area was B16.7% of the striatal area. The total number of GFP-expressing cells in the transduced striatum, as assessed by stereology, was 46 57872938 (n = 4), equivalent to about 1 cell/40 TU. In the lower dose group, there was proportionally fewer GFP-expressing cells located close to the injection site. Over 90% of the transduced cells in the striatum had a neuronal morphology (Fig. 1e) with the appearance of both medium-sized spiny and aspiny neurons. A small number of transduced cells displayed an astroglial morphology as well as an oligodendrocyte-like morphology (Fig. 1f, g ). There were no signs of any overt toxic damage or immune reactions in the striatum as assessed by inspection of cresyl violet stained sections.
The transduction of striatal projection neurons resulted in an intra-axonal anterograde transport of GFP along the striatonigral pathway to the GP (Fig. 1b) , entopeduncular nucleus (Fig. 1c) and SN (Fig. 1d) . Dense GFP-positive terminal networks were present in all the three striatal output nuclei. All GFP immunoreactivity was located intracellularly, and no signs of retrograde transport of GFP were observed in any of the major afferents to the striatum.
Expression and distribution of GDNF: Immunohistochemistry was used to visualize the distribution of the GDNF protein at 6 weeks after injection of rLV-GDNF vector (1 Â 10 4 TU) in the striatum. Immunoreactive GDNF was widely distributed within the striatum and extended into the overlying corpus callosum and the deep layers of the neocortex laterally (Fig. 2a) . The diffuse extracellular localization of the GDNF immunoreactivity is consistent with secretion of GDNF from the transduced cells and good diffusion properties of the GDNF protein. GDNF immunoreactivity could also be observed in more caudal structures due to anterograde transport and release of the GDNF protein along the axons of the striatal projection neurons to the GP (Fig. 2b), entopeduncular nucleus (Fig. 2c) and SN  (Fig. 2d) .
GDNF-positive cells were observed in the GP, entopeduncular nucleus and pars reticulata of the SN (data not shown). The morphology and distribution of these cellular profiles suggests that they represent cells that had accumulated anterogradely transported GDNF released from the terminals of the transduced striatal neurons. This cellular accumulation of GDNF may be mediated by the GFRa-1 receptor which is highly expressed precisely in the areas where GDNF-positive cells occurred [11] .
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To determine the correlation between the number of TU injected and the level of GDNF expression, increasing doses of the rLV-GDNF vector (ranging from 3.6 Â 10 4 TU to 3.6 Â 10 5 TU) were injected in the striatum (Fig. 2e) . The levels of GDNF obtained ranged from 1.7 to 9.3 ng/mg tissue in the striatum and 0.5-3.0 ng/mg tissue in the SN, and a highly significant linear correlation ( po0.0001) was observed in both structures (Fig. 2e) . To determine the timecourse of GDNF expression, GDNF protein levels were assessed by ELISA in tissue samples obtained from animals killed at different times after the striatal rLV-GDNF injections, at a dose of 2 Â 10 5 TU (Fig. 2f) . Detectable levels of GDNF protein were measured in both striatum and SN as early as 4 days after the vector injection. The expression was sustained at 6 weeks and still maintained at 8 months at about 50% of the level measured at 6 weeks. The levels of GDNF in the transduced striatum (0.9-2.4 ng/mg tissue) were about 10-fold higher than the levels detected in the ipsilateral SN (0.2-0.3 ng/mg tissue; effect of structure, F(1, 88) = 82.65, po0.0001). No detectable levels of GDNF could be measured on the non-transduced side (effect of side, F(1, 44) = 68.98, po0.0001 for striatum and F(1, 44) = 17.34, po0.0001 for SN). To determine whether the rLV-GFP control vector had an effect on the endogenous GDNF level, we included a GFP treated group at 6 weeks. The GDNF levels measured on the rLV-GFP injected side did not differ from either the contralateral side in the control animals, or from the non-transduced side in the rLV-GDNF injected animals.
Locomotor activity and motor asymmetry in intact animals: The effect of striatal GDNF overexpression on locomotor activity and rotational motor asymmetry in intact animals was assessed 3 weeks after the rLV-GDNF injection, just prior to the 6-OHDA lesion (Table 1) . Spontaneous locomotor activity was not significantly different between the groups. However, when injected with amphetamine, the rLV-GDNF animals displayed an increased activity, which reached significance in the high-dose rLV-GDNF group (F(2,16) = 12.82, po0.001). The rLV-GDNF-treated animals displayed, in addition, an enhanced contralateral turning bias (right-left), both spontaneously, (F(2,16) = 7.99, po0.01) and after amphetamine (F(2,16) = 11.94, po0.001; Table 1 ). The rate of amphetamine-induced turning was significantly higher in the rLV-GDNF group receiving the higher dose of vector (1 Â 10 4 TU), compared to the low-dose group (2 Â 10 4 TU), suggesting that the magnitude of the functional effect was related to the amount of rLV-GDNF vector injected in the striatum.
Protection of nigral DA neurons against the 6-OHDA lesion: The neuroprotective effect of GDNF for nigral DA neurons was studied by transduction of the striatum with rLV vectors at two doses, 2 Â 10 3 TU or 1 Â 10 4 TU. In the rLV-GFP injected controls, the lesion induced an extensive loss of TH-positive neurons (B72%) in the SN pars compacta as compared with the intact hemisphere (Fig. 3d, compare a and b) . The TH-positive cell numbers in the rLV-GDNF groups amounted to 65% and 77% of the intact side in the low and high dose groups, respectively ( Fig. 3d; compare a and c) . There was no significant difference between the two GDNF treated groups.
Sprouting of lesioned TH-positive fibers: In the control animals, the 6-OHDA lesion induced an extensive loss of TH-positive nigrostriatal axons passing along the internal capsule and through the GP (Fig. 4, compare a and b, d and e). In the GDNF groups preservation of the pathway, seen as TH-positive fibers with normal appearance and organization, and intense sprouting was observed within the GP (Fig. 4f,f 0 ) and entopeduncular nucleus (not shown), as well as in the medial aspects of the striatum, bordering on the GP. The areas where substantial sprouting occurred corresponded precisely to the distribution of anterogradely transported GDNF, as detected with the GDNF antibody (Fig. 2) . The sprouting response appeared similar in both entopeduncular nucleus and GP, although it was more substantial in the GP. The sprouting fibers were densely stained and appeared disorganized (Fig. 4f  0 ) . Although there was an intense sprouting response in the GP and medial striatum, the fibers failed to reinnervate the denervated parts of striatum (Fig. 4c) . Densitometry measurements of the striatal TH innervation showed that all groups were equally denervated (20.876.1% in the rLV-GDNF groups; 20.678.5% in the rLV-GFP group, p40.05). Consistent with this, all groups displayed strong amphetamine-induced rotation in the post-operative test, performed 3 weeks after the striatal 6-OHDA lesion (14.175.7 turns/min in rLV-GDNF groups; 16.373.1 turns/min in rLV-GFP group, p40.05). Â10 4 TU) in the striatum was visualized by immunohistochemistry after 6 weeks survival.Transduced GDNF was widely distributed throughout the striatum (a) and was also detected along the pathway of the striatal projection neurons to the GP (b), entopeduncular nucleus (c) and SN (d). Ac, anterior commissure; cc, corpus callosum; cp, cerebellar peduncle; EP, entopeduncular nucleus; GP, globus pallidus; ic, internal capsule; lv, lateral ventricle; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata, Str, striatum;Th, thalamus. Bar = 1mm (a^d). (e) The amount of injected vector and the GDNF levels (ng/mg tissue), as measured by ELISA, in the striatum and SN, after injection of increasing doses of rLV-GDNF in the striatum (3.6 Â10 
DISCUSSION
The present results confirm and extend previous studies, showing that overexpression of GDNF in the nigrostriatal system by the rLV vector system can efficiently rescue nigral TH-positive neurons from 6-OHDA-induced toxic damage. The level of cell rescue obtained here, using intrastriatal injections of the rLV-GDNF vector (65-77% of the intact side) was at least as good as that obtained when the vector was administered over the SN (56-70%) [4, 5] . Neither intranigral [4] nor intrastriatal rLV-GDNF delivery was able to protect the TH-positive terminals in the striatum against the direct toxic action of the intrastriatal 6-OHDA injection. However, the intrastriatal route of vector delivery was highly effective in preserving the integrity of the axons along the nigrostriatal pathway, and there was substantial sprouting from the preserved axons, which is in line with what has been obtained with intrastriatal injections of recombinant GDNF protein [10] , or over-expression of GDNF in the striatum by rAAV or adenoviral vectors [11, 19, 20] .
Efficiency of the rLV vector:
The VSV-G pseudotyped rLV vector is highly efficient in transducing neurons in the adult striatum. An average of about 50 000 GFP-positive cells (mostly neurons), corresponding to 1 cell/40 TU were detected after injection of 3 Â 1 ml of the vector at high dose, covering about 17% of the total striatal area. This compares well with the data of Déglon et al. [5] and Bensadoun et al. [4] after injection of a similar high-titer rLV-GDNF vector over the SN: 21 800 mesencephalic cells from a 2 ml injection in the rat, and 38 000 mesencephalic cells from a 1 ml injection in the mouse. The efficiency of the vector is further increased by the anterograde transport of the transduced protein along the axons of the striatal projection neurons to other basal ganglia structures, such as GP, entopeduncular nucleus and SN, as observed for both GFP and GDNF. While GFP is retained within the axons, GDNF is clearly released extracellularly and thus able to exert actions also within the striatal target structures. The striatal tissue levels of GDNF obtained with the present rLV-GDNF vector (1.770.1 ng/ mg tissue with 3.6 Â 10 4 TU and 9.371.1 ng/mg tissue with 3.6 Â 10 5 TU) were clearly dose dependent and are the highest reported so far from any vector system (see Table 1 in ref. [21] ). Indeed, the GDNF levels measured in the SN (0.5-3.0 ng/mg tissue), generated by anterograde transport along the striatonigral axons from the transduced striatum, were higher than those previously obtained after direct injection of rLV-GDNF vector into the SN (B0.5-0.6 ng/mg tissue) [4] . These SN tissue levels are well in the range required for the induction of a good biological effect, i.e. near maximal neuroprotection in the 6-OHDA lesion model [22] (see [21] for further discussion).
Stimulation of DA function in intact animals: In intact animals, GDNF has been shown to exert a stimulatory effect on DA turnover in striatum and/or SN. This effect has been observed after single bolus injections of GDNF, in doses of 1-10 mg, into either SN [23] [24] [25] or striatum [26, 27] , and is accompanied by increased spontaneous [24, 25, 27] or amphetamine-induced locomotor activity [23, 25, 26] . These effects persist for ! 1 week after injection, which is consistent with the fact that immunoreactive GDNF is detectable in the injected area for ! 1 week after single intracerebral injection [10] . In line with these data we have observed that overexpression of GDNF unilaterally in either striatum or SN induces a marked turning bias, either spontaneously or after amphetamine injection (present data and [11] ). In the Kirik et al. study [11] , using a rAAV vector to deliver GDNF to striatum and/or SN, these behavioral effects were accompanied by a 2-to 3-fold increase in DA turnover in the ipsilateral striatum 3 weeks after vector delivery. Taken together, these data indicate that GDNF has a direct stimulatory effect on the intact nigrostriatal system and that this effect can be elicited not only by single bolus injections or the protein, but also by sustained overexpression of the factor in either striatum or SN. In fact, from the present results and other ongoing experiments (Georgievska et al., to be published) it seems that amphetamine-induced rotation provides a convenient and sensitive in vivo test to monitor the level of GDNF expression in gene transfer experiments where the vector is delivered unilaterally, prior to other experimental manipulations.
Neuroprotective effects of intrastriatal rLV-GDNF delivery: The present data indicate that intrastriatal delivery of the rLV-GDNF vector is at least as effective as nigral delivery in protecting the nigral TH-positive cell bodies against 6-OHDA-induced damage, as reported by Bensadoun et al. [4] . In our previous study [8] we observed a small but significant rescue of the striatal TH-positive innervation when the rLV-GDNF vector was injected in both nigra and striatum (24.2% of normal innervation in the rLV-GDNF group compared to 17.5% of normal in the rLV-GFP controls). No sparing of the striatal innervation was detectable here when the vector was injected in the striatum only. Most significantly, however, we observed a partial sparing of the axons of the nigrostriatal pathway, extending along the internal capsule and through the GP, and there was a prominent sprouting from the spared TH-positive axons in the GP and the entopeduncular nucleus, as well as in the medial aspects of the striatum, adjacent to the GP. The distribution of the sprouting TH-positive fibers coincided with areas where high levels of GDNF were detectable in the immunostained sections. The failure of the sprouting axons to provide any significant reinnervation of the striatum may, at least in part, be explained by the short survival time, 3 weeks post-lesion, used in the present experiment. From our previous study, using the rAAV-GDNF vector, it seems that functional recovery develops gradually over the first 2-3 months after the lesion, and a significant increase in striatal TH-positive innervation was not observed until 6 months after the lesion, from about 10% of normal in the controls to 25-30% of normal in the rAAV-GDNF treated animals [11] .
CONCLUSION
The present results confirm and extend previous findings, showing that the rLV-GDNF vector is able to induce sustained expression of GDNF in the striatum, and that over-expression of GDNF in the striatum alone is sufficient to provide marked rescue of the nigral DA cell bodies and preserve the nigrostriatal axons in the 6-OHDA lesion model. Substantial regenerative sprouting was observed from the spared axons into the areas of high GDNF expression.
